Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
Orgaran, a heparinoid, has been used successfully in patients with heparin-induced thrombocytopenia. We report three cases in which Orgaran was combined with the glycoprotein IIbIIa receptor antagonist Reopro during coronary angioplasty. Orgaran was given as a single intravenous bolus of 1500 anti-factor Xa units. No ischemic or hemorrhagic complications occurred during or following the procedure.
Cantor
W J
WJ
Department of Internal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
Leblanc
K
K
Garvey
B
B
Watson
K R
KR
Rasymas
A
A
Strauss
B H
BH
D000077284:Abciximab; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D000077284:Abciximab; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; C035838:danaparoid